- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06150469
Efficacy of Inhaled Aromatherapy on Nausea and Vomiting in Hematological Malignancies (AROM-HEMATO)
Efficacy of Ginger and Lemon Essential Oil Inhalation on Chemotherapy-induced Nausea and Vomiting in Patients With Haematological Malignancies: a Multicenter, Double-blind, Randomised Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The aim is to evaluate the efficacy of inhalation of a mixture of ginger and lemon Essential Oils (EO) versus placebo in addition to conventional antiemetic treatments on the intensity of chemo-induced nausea during the acute phase D1 (H24) of its onset in patients with C1 haematological malignancies.
This multicentre study will be carried out in 5 establishments (haematology and oncology care sectors), which represents a very high potential for inclusion.
In addition, the investigator expect a very high acceptance rate for this study. In fact, in the context of CINV, this care strategy may meet a patient's expectation of symptoms (nausea, vomiting) that they find difficult to manage. Finally, it is known that patients in these care sectors are very keen on supportive care to improve their quality of life, so this is a potentially very interesting opportunity without any particular risk that is offered to participants in this study.
A nurse and a doctor with a postgraduate diploma in aromatherapy are coordinating the team, with the support of a nurse trained in evidence-based practice research methodology. Institutional procedures drawn up by the team at Limoges University Hospital describe the general procedure for using aromatherapy in a scientific and safe way, the protocols that can be used to describe the operating methods, the traceability of the manufacture of the mixtures and their administration, and the evaluation of their effectiveness. Supporting documents, an information note and a monitoring sheet have been created and are being used.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Limoges, France, 87042
- University Hospital, Limoges
-
Contact:
- Jean TONIOLO
- Phone Number: 0555055555
- Email: Jean.TONIOLO@chu-limoges.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients aged over 18 years,
- Chemo-naive patients at inclusion,
- Patients with haematological malignancies treated treated with chemotherapy,
- Patients physically and mentally able to use the aromastick,
- Patients who speak, read and write French,
- Patients who have given signed consent,
- Patients with social security cover.
Exclusion Criteria:
- Asthmatic patients.
- Patients with anosmia.
- Patients allergic to EO, lemon or ginger.
- Patients who have already received aromatherapy to treat chemotherapy-induced nausea and vomiting,
- Patients practising herbal medicine or acupuncture,
- Pregnant and breast-feeding women,
- Patients under guardianship, tutorship or curatorship,
- Patients taking part in interventional studies involving antiemetic drugs or nutritional products,
- Patients who have already had cancer.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Blend of ginger and lemon essential oils
The experimental group will benefit from conventional management of NVCI (antiemetic prophylaxis in accordance with ESMO international recommendations) plus an aromastick of ginger and lemon essential oils renewed with each course of chemotherapy. Patients were included for 3 cycles of chemotherapy (C1, C2, C3). |
Patients will be given aromasticks to inhale the blend of essential oils.
|
Placebo Comparator: Neutral oil
The control group will receive conventional management (antiemetic prophylaxis according to international recommendations, ESMO) of NVCI plus a placebo of aromastick containing a neutral, odourless oil, renewed with each course of chemotherapy.
|
Patients will be given aromasticks to inhale the blend of essential oils.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of inhaled aromatherapy on acute nausea
Time Frame: 1 month, 2 months and 3 months
|
To assess difference of nausea intensity score measured by MAT Tool between groups oils (EO) of ginger and lemon versus placebo in addition to addition to conventional antiemetic treatments on intensity of chemo-induced nausea during the acute phase D1 (H24) of onset in patients with haematological malignancies C1 haematological malignancies. MAT is used to self-assess the prevention and control of chemotherapy-induced nausea and vomiting. It comprises 2 evaluation parts: the first is a Likert scale assessing the intensity of chemotherapy-induced nausea (0-10), and the second is a record of the frequency of vomiting in the acute (H24) and delayed (H96) phases of chemo-induced nausea and vomiting onset. |
1 month, 2 months and 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of inhaled aromatherapy on vomiting frequency
Time Frame: 1 day, 1 month
|
To evaluate difference of vomiting fréquency measure by MAT Tool between groups. MAT is used to self-assess the prevention and control of chemotherapy-induced nausea and vomiting. It comprises 2 evaluation parts: the first is a Likert scale assessing the intensity of chemotherapy-induced nausea (0-10), and the second is a record of the frequency of vomiting in the acute (H24) and delayed (H96) phases of chemo-induced nausea and vomiting onset. |
1 day, 1 month
|
Efficacy of inhaled aromatherapy on acute nausea between 4 days and 1 month
Time Frame: 4 days, 1 month
|
To assess difference of nausea intensity score measured by MAT Tool between groups. MAT is used to self-assess the prevention and control of chemotherapy-induced nausea and vomiting. It comprises 2 evaluation parts: the first is a Likert scale assessing the intensity of chemotherapy-induced nausea (0-10), and the second is a record of the frequency of vomiting in the acute (H24) and delayed (H96) phases of chemo-induced nausea and vomiting onset. |
4 days, 1 month
|
Efficacy of inhaled aromatherapy on vomiting frequency between 4 days and 1 month
Time Frame: 4 days, 1 month
|
To evaluate difference of vomiting fréquency measure by MAT Tool between groups. MAT is used to self-assess the prevention and control of chemotherapy-induced nausea and vomiting. It comprises 2 evaluation parts: the first is a Likert scale assessing the intensity of chemotherapy-induced nausea (0-10), and the second is a record of the frequency of vomiting in the acute (H24) and delayed (H96) phases of chemo-induced nausea and vomiting onset. |
4 days, 1 month
|
Efficacy of inhaled aromatherapy
Time Frame: 1 month, 2 months and 3 months
|
To compare the efficacy of inhaled aromatherapy on the evolution of nausea intensity in the acute phase acute phase (D1) and then the delayed phase (D4) chemotherapy cycles (C1, C2 and C3). MAT is used to self-assess the prevention and control of chemotherapy-induced nausea and vomiting. It comprises 2 evaluation parts: the first is a Likert scale assessing the intensity of chemotherapy-induced nausea (0-10), and the second is a record of the frequency of vomiting in the acute (H24) and delayed (H96) phases of chemo-induced nausea and vomiting onset. |
1 month, 2 months and 3 months
|
Anticipatory nausea
Time Frame: 1 month, 2 months and 3 months
|
Compare the intensity of chemo-induced nausea.
Compared the mean difference of anticipatory nausea intensity score measured by a Likert scale (ranging from 0-10 with zéro none and 10 as much as possible) between groups before the start of each cycle of chemotherapy (C1, C2, C3) between groups.
|
1 month, 2 months and 3 months
|
Compare the proportion of chemically-induced emesis
Time Frame: 1 month, 2 months and 3 months
|
Compare the proportion of chemically-induced emesis before the start of each cycle of chemotherapy (C1, C2, C3) between groups.
|
1 month, 2 months and 3 months
|
Independent determinants of the presence of nausea then vomiting
Time Frame: 1 month, 2 months and 3 months
|
To identify, in patients who received aromatherapy, the association between independent determinants of the presence of nausea then vomiting at the acute phase (D1) and at the delayed phase (D4) of the first cycle of chemotherapy (C1) (sex, age, anticipation of CINV, nausea terrain, history of nausea/vomiting, history of chemotherapy, motion sickness, tolerance of EO odour).
|
1 month, 2 months and 3 months
|
Compare and describe the use of antiemetics use of antiemetics
Time Frame: 1 month, 2 months and 3 months
|
Compare and describe the use of antiemetics use of antiemetics and write down the use of EO inhalations EO inhalations "if needed" during the acute (D1), delayed (D4) and anticipated phase of CINV (H0) during the 3 cycles of chemotherapy (C1, C2 and C3).
|
1 month, 2 months and 3 months
|
Impact of inhaled aromatherapy on quality of life
Time Frame: 1 month, 2 months and 3 months
|
Compare quality of life between the two groups at each each cycle of chemotherapy (C1,C2 and C3). Difference of quality of life score (EORTC QLQC30) between groups at each cycle. EORTC QLQC 30 is European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire. This self-questionnaire, validated in French, assesses quality of life specific to cancer. It is intended for all cancer patients, regardless of location. EORTC QLQC 30 contains 30 items and assesses 15 dimensions of quality of life :
|
1 month, 2 months and 3 months
|
Efficacy of inhaled aromatherapy on dietary intake
Time Frame: 1 month, 2 months and 3 months
|
To compare the effect of inhalation of ginger + lemon EO versus placebo in addition to conventional antiemetic treatments on diet during C1, C2, C3. Difference of dietary intake measured by SEFI scale between groups. SEFI (Score d'Evaluation Facile des Ingesta - Ingesta Easy Evaluation Score) / LA description : SEFI is a visual assessment, by the patient himself or with the help of a caregiver, of his food intake, using an analog scale (0 to 10), or a choice of portions consumed. |
1 month, 2 months and 3 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 87RI23_0013-AROM-HEMATO
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematological Malignancies
-
Tel-Aviv Sourasky Medical CenterMeir Medical Center; Max Planck Institute for Infection BiologyUnknownPediatric Solid Malignancies | Pediatric Hematological MalignanciesIsrael
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingRelapsed/Refractory Hematological MalignanciesChina
-
AdaptimmuneRecruitingSolid and Hematological MalignanciesUnited States, Spain, Canada, United Kingdom
-
Kite, A Gilead CompanyEnrolling by invitationSolid and Hematological MalignanciesUnited States, Netherlands, Japan, Australia, France, Israel, Germany, Canada, United Kingdom
-
AstraZenecaParexelCompletedSolid and Hematological MalignanciesGermany
-
Baylor College of MedicineCenter for Cell and Gene Therapy, Baylor College of MedicineCompletedMyeloid Hematological MalignanciesUnited States
-
Centre Hospitalier Universitaire de BesanconTerminatedHematological Malignancies BFrance
-
AdaptimmuneTerminatedSolid and Hematological MalignanciesUnited States, Canada
-
Senti BiosciencesRecruitingAML/MDS | CD33 Expressing Hematological Malignancies | FLT3 Expressing Hematological MalignanciesUnited States, Australia
-
CASI Pharmaceuticals, Inc.CompletedRelapsed or Refractory Hematological MalignanciesCanada
Clinical Trials on "Blend of ginger and lemon essential oils", "Neutral oil"
-
Özlem ÇağanCompletedAnxiety | Aromatherapy | Pain, LaborTurkey
-
Franklin Health ResearchCompletedStress | Burnout, Professional | Stress, JobUnited States
-
The University of Texas Health Science Center,...HCA Houston Healthcare Southeast HospitalCompletedPostoperative Nausea and Vomiting (PONV)United States
-
Clinica Luganese MoncuccoCompletedBPSD (Behavioral and Psycological Symptoms of Dementia)Switzerland
-
Tokat Gaziosmanpasa UniversityCompleted
-
Milton S. Hershey Medical CenterDoctors Kienle Center for Humanistic Medicine/Penn State College of MedicineTerminatedNausea | VomitingUnited States
-
Jieqiong CuiNot yet recruitingDepressive Disorder | Mental Disorder in Adolescence
-
Groupe Hospitalier de la Region de Mulhouse et...CompletedIntensive Care Unit DeliriumFrance
-
Stanford UniversityTerminatedStage IV Nasopharyngeal Carcinoma | Stage III Nasopharyngeal Carcinoma | Stage IVA Nasopharyngeal Carcinoma | Stage IVB Nasopharyngeal Carcinoma | Stage II Nasopharyngeal Carcinoma | Stage 0 Nasopharyngeal Carcinoma | Stage 0 Paranasal Sinus Cancer | Stage I Nasopharyngeal Carcinoma | Stage I Paranasal... and other conditionsUnited States
-
Balanced Health plusWake Forest University Health SciencesUnknown